Harrow, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Harrow, Inc. (HROW) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $356.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-02
- Harrow, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2012-12-31 was $0.00.
- Harrow, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $356.00K.
- Harrow, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2011 was $10.12K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|---|
| 2025-12-31 | $356.00K 10-K · filed 2026-03-02 | |
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 | |
| 2011-12-31 | $10.12K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |